个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共31条记录   Heterogeneity Maintenance in Glioblastoma: A Social Network [作者：Bonavia, R; Inda, MD; Cavenee, WK; Furnari, FB,期刊：Cancer research, 页码：4055-4060 , 文章类型： Review，,卷期：2011年71-12] Glioblastoma multiforme (GBM), the most common intracranial tumor in adults, is characterized by extensive heterogeneity at the cellular and molecular levels. This insidious feature arises inevitably in almost all cancer... PIK3R1 (p85 alpha) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer [作者：Urick, ME; Rudd, ML; Godwin, AK; Sgroi, D; Merino, M; Bell, DW,期刊：Cancer research, 页码：4061-4067 , 文章类型： Article，,卷期：2011年71-12] Phosphoinositide 3-kinase (PI3K) is an important therapeutic target. Mutations in PIK3CA, which encodes p110 alpha, the catalytic subunit of PI3K, occur in endometrioid endometrial cancers (EEC) and nonendometrioid endom... Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors [作者：Zindy, P; Berge, Y; Allal, B; Filleron, T; Pierredon, S; Cammas, A; Beck, S; Mhamdi, L; Fan, L; Favre, G; Delord, JP; Roche, H; Dalenc, F; Lacroix-Triki, M; Vagner, S,期刊：Cancer research, 页码：4068-4073 , 文章类型： Article，,卷期：2011年71-12] Elucidating how cancer cells respond to antagonists of HER receptor family members is critical to understanding mechanisms of therapeutic resistance that arise in patients. In large part, resistance to such agents appear... mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment [作者：Jiang, Q; Weiss, JM; Back, T; Chan, T; Ortaldo, JR; Guichard, S; Wiltrout, RH,期刊：Cancer research, 页码：4074-4084 , 文章类型： Article，,卷期：2011年71-12] mTOR is a central mediator of cancer cell growth, but it also directs immune cell differentiation and function. On this basis, we had explored the hypothesis that mTOR inhibition can enhance cancer immunotherapy. Here, w... Targeting Hyaluronidase for Cancer Therapy: Antitumor Activity of Sulfated Hyaluronic Acid in Prostate Cancer Cells [作者：Benitez, A; Yates, TJ; Lopez, LE; Cerwinka, WH; Bakkar, A; Lokeshwar, VB,期刊：Cancer research, 页码：4085-4095 , 文章类型： Article，,卷期：2011年71-12] The tumor cell-derived hyaluronidase (HAase) HYAL-1 degrades hyaluronic acid (HA) into proangiogenic fragments that support tumor progression. Although HYAL-1 is a critical determinant of tumor progression and a marker f... A Novel Function of Junctional Adhesion Molecule-C in Mediating Melanoma Cell Metastasis [作者：Langer, HF; Orlova, VV; Xie, CP; Kaul, S; Schneider, D; Lonsdorf, AS; Fahrleitner, M; Choi, EY; Dutoit, V; Pellegrini, M; Grossklaus, S; Nawroth, PP; Baretton, G; Santoso, S; Hwang, ST; Arnold, B; Chavakis, T,期刊：Cancer research, 页码：4096-4105 , 文章类型： Article，,卷期：2011年71-12] Hematogenous dissemination of melanoma is a life-threatening complication of this malignant tumor. Here, we identified junctional adhesion molecule-C (JAM-C) as a novel player in melanoma metastasis to the lung. JAM-C ex... Nonredundant Functions for Akt Isoforms in Astrocyte Growth and Gliomagenesis in an Orthotopic Transplantation Model [作者：Endersby, R; Zhu, XY; Hay, N; Ellison, DW; Baker, SJ,期刊：Cancer research, 页码：4106-4116 , 文章类型： Article，,卷期：2011年71-12] The AKT family, comprising three highly homologous kinases, is an essential mediator of the PTEN/PI3K pathway, which is deregulated in many human cancers. A thorough understanding of the specific activities of each isofo... Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias [作者：Kvinlaug, BT; Chan, WI; Bullinger, L; Ramaswami, M; Sears, C; Foster, D; Lazic, SE; Okabe, R; Benner, A; Lee, BH; De Silva, I; Valk, PJM; Delwel, R; Armstrong, SA; Dohner, H; Gilliland, DG; Huntly, BJP,期刊：Cancer research, 页码：4117-4129 , 文章类型： Article，,卷期：2011年71-12] Fusion oncogenes in acute myeloid leukemia (AML) promote self-renewal from committed progenitors, thereby linking transformation and self-renewal pathways. Like most cancers, AML is a genetically and biologically heterog... Quantitative, Noninvasive Imaging of Radiation-Induced DNA Double-Strand Breaks In Vivo [作者：Li, WR; Li, F; Huang, Q; Shen, JP; Wolf, F; He, YJ; Liu, XJ; Hu, YA; Bedford, JS; Li, CY,期刊：Cancer research, 页码：4130-4137 , 文章类型： Article，,卷期：2011年71-12] DNA double-strand breaks (DSB) are a major form of DNA damage and a key mechanism through which radiotherapy and some chemotherapeutic agents kill cancer cells. Despite its importance, measuring DNA DSBs is still a tedio... Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth [作者：Chen, J; Zhang, B; Wong, N; Lo, AWI; To, KF; Chan, AWH; Ng, MHL; Ho, CYS; Cheng, SH; Lai, PBS; Yu, J; Ng, HK; Ling, MT; Huang, AL; Cai, XF; Ko, BCB,期刊：Cancer research, 页码：4138-4149 , 文章类型： Article，,卷期：2011年71-12] Hepatocellular carcinoma (HCC) is a highly malignant tumor with a poor prognosis. Treatment of HCC is complicated by the fact that the disease is often diagnosed at an advanced stage when it is no longer amenable to cura... Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells Is Abrogated by IFN-beta and Valproic Acid [作者：Roos, WP; Jost, E; Belohlavek, C; Nagel, G; Fritz, G; Kaina, B,期刊：Cancer research, 页码：4150-4160 , 文章类型： Article，,卷期：2011年71-12] Malignant melanoma, once metastasized, has a dismal prognosis because of intrinsic resistance to anticancer drugs. First-line therapy includes the methylating agents dacarbazine and temozolomide. Although DNA mismatch re... Identification of Aldo-Keto Reductase AKR1B10 as a Selective Target for Modification and Inhibition by Prostaglandin A(1): Implications for Antitumoral Activity [作者：Diez-Dacal, B; Gayarre, J; Gharbi, S; Timms, JF; Coderch, C; Gago, F; Perez-Sala, D,期刊：Cancer research, 页码：4161-4171 , 文章类型： Article，,卷期：2011年71-12] Cyclopentenone prostaglandins (cyPG) are reactive eicosanoids that may display anti-inflammatory and antiproliferative actions, possibly offering therapeutic potential. Here we report the identification of members of the... Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations [作者：Osada, T; Chen, MY; Yang, XY; Spasojevic, I; Vandeusen, JB; Hsu, D; Clary, BM; Clay, TM; Chen, W; Morse, MA; Lyerly, HK,期刊：Cancer research, 页码：4172-4182 , 文章类型： Article，,卷期：2011年71-12] Wnt/beta-catenin pathway activation caused by adenomatous polyposis coli (APC) mutations occurs in approximately 80% of sporadic colorectal cancers (CRC). The antihelminth compound niclosamide down-regulates components o... Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting Salmonella-Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors [作者：Manuel, ER; Blache, CA; Paquette, R; Kaltcheva, TI; Ishizaki, H; Ellenhorn, JDI; Hensel, M; Metelitsa, L; Diamond, DJ,期刊：Cancer research, 页码：4183-4191 , 文章类型： Article，,卷期：2011年71-12] Cancer vaccine therapies have only achieved limited success when focusing on effector immunity with the goal of eliciting robust tumor-specific T-cell responses. More recently, there is an emerging understanding that eff... Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer [作者：Rao, M; Chinnasamy, N; Hong, JA; Zhang, YW; Zhang, M; Xi, SC; Liu, F; Marquez, VE; Morgan, RA; Schrump, DS,期刊：Cancer research, 页码：4192-4204 , 文章类型： Article，,卷期：2011年71-12] Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms... Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a [作者：Brennan, RC; Federico, S; Bradley, C; Zhang, JK; Flores-Otero, J; Wilson, M; Stewart, C; Zhu, FY; Guy, K; Dyer, MA,期刊：Cancer research, 页码：4205-4213 , 文章类型： Article，,卷期：2011年71-12] Retinoblastoma is a rare childhood cancer of the retina that begins in utero and is diagnosed in the first years of life. The goals of retinoblastoma treatment are ocular salvage, vision preservation, and reduction of sh...